NeoBiotechnologies sets a new benchmark in monoclonal antibody production as an original manufacturer delivering an extensive portfolio of over 10,000 expertly designed monospecific antibodies. In a crowded market full of resellers who rebrand products produced by a small contingent of manufacturers, NeoBiotechnologies stands apart. By controlling every step of production— development to rigorous validation—NeoBiotechnologies ensures a level of quality and reliability that no competitor can rival.
This hands-on approach addresses a critical issue identified by the National Institutes of Health (NIH): nearly 70% of published research is irreproducible due to antibodies lacking monospecificity. Non-specific antibodies frequently bind to unintended targets, leading to flawed conclusions, wasted resources, and setbacks in research.
Rigorous testing and validation allow NeoBiotechnologies to produce highly specific antibodies, reacting exclusively with their intended targets and consistently meeting quality benchmarks. This comprehensive dedication to precision ensures consistent results across applications, including solid tumor analysis, liquid biopsies, urine, and sputum samples—fully equipping researchers and diagnosticians with accurate, reproducible data that advances their work instead of precluding it.
“With over 80% of our team dedicated to in-house testing, we ensure unmatched precision and reliability through rigorous development and characterization,” says Dr. Atul Tandon, President and CEO.
Widely known as “the MabMan”—the Monoclonal Antibody Man—for his groundbreaking contributions to the field, Dr. Tandon’s journey into monoclonal antibody technology began in the 1980s, when the field was still in its infancy. While conducting breast cancer research at the University of Texas Health Science Center, he identified a critical inefficiency: researchers were often unknowingly purchasing identical antibodies from different companies, rebranded and sold at inflated prices. This practice drained research budgets and wasted valuable time that should have been directed toward advancing discovery.
Determined to meet this challenge, he transitioned from academia to establish NeoMarkers, a company dedicated to providing high-quality antibodies to the scientific community. Building on this foundation, he launched NeoBiotechnologies in 2013 with a mission to redefine the monoclonal antibody field through uncompromising quality and cutting-edge innovation. Today, NeoBiotechnologies is recognized globally for its contributions to research, diagnostics, and therapeutic applications across oncology, immunology, neuroscience, and metabolism.
A relentless focus on innovation sets NeoBiotechnologies apart. One of its crowning achievements is the development of a robust portfolio of rabbit recombinant monoclonal antibodies, renowned for their purity, sensitivity and specificity, making them indispensable in addressing complex medical challenges.
“By controlling every step of production – development to rigorous validation – NeoBiotechnologies ensures a level of quality and reliability that no competitor can rival“
The company introduces nearly 1,000 new products each year—an extraordinary feat in the industry, where most players are constrained by external manufacturing timelines. Its vertically integrated production model accelerates development enabling it to quickly respond to emerging research demands. This impressive pipeline is guided by close collaboration with the scientific community, ensuring that every new product addresses critical gaps in the market.
NeoBiotechnologies prides itself on its customer-centric approach, ensuring that all products are readily available for immediate shipping. Researchers benefit from the convenience of placing an order and receiving it within a day, minimizing delays in critical projects. It offers all products in trial sizes, allowing customers to test and validate the antibodies before committing to larger quantities.
A robust B2B marketing strategy underpins its presence in over 200 countries. Collaborations with industry giants like Thermo-Fisher and OEM agreements amplify its reach, enabling NeoBiotechnologies’ products to be marketed under various brand names while maintaining their integrity and quality.
Operating as a fully self-funded enterprise, NeoBiotechnologies remains free from the constraints of investors and shareholders, allowing it to prioritize its mission of advancing science above all else, reinvesting profits into R&D rather than dividends. With its commitment to innovation, precision and customer satisfaction, NeoBiotechnologies is not just competing in the antibody industry—it’s redefining it.
President and CEO.
